Holen Sie sich die Stockscreener-App
92.22
4.02%
3.56
Handel nachbörslich:
92.22
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Alcon Inc Aktie (ALC) Neueste Nachrichten
Alcon Inc. Stock Analysis and ForecastConsistent wealth multiplication - Autocar Professional
Should You Continue to Hold Alcon (ALC)? - Insider Monkey
What analysts say about Alcon Inc. stockDynamic profit opportunities - Autocar Professional
What drives Alcon Inc. stock priceFree Trading Strategy Suggestions - jammulinksnews.com
Is Alcon Inc. a good long term investmentFree Consultation - jammulinksnews.com
Alcon Helps with Back-to-School Prep - MyStateline
RBC Sticks With Alcon As Equipment Sales Lead Growth - Finimize
Swiss Stocks Slip As Roche And Alcon Weigh On The Index - Finimize
US Federal Trade Commission: FTC approves final order settling charges that Novartis AG’s acquisition of Alcon, Inc. was anticompetitive in U.S. eye care market - MLex
Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders - Yahoo Finance
September 19th Options Now Available For Alcon (ALC) - Nasdaq
Alcon Stock Gains Following UNITY VCS' Approval in Canada - MSN
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients - Ophthalmology Times Europe
Stifel Nicolaus Sticks to Their Buy Rating for Alcon (ALC) - The Globe and Mail
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target - Investing.com Nigeria
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions - Eyes On Eyecare
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target By Investing.com - Investing.com South Africa
Alcon Adds Noninvasive Treatment Solution, Acquires LumiThera | Business | Jul 2025 - Photonics Spectra
Alcon Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - VisionMonday.com
Alcon sees the light with Lumithera buy for dry AMD - BioWorld MedTech
Alcon’s vitreoretinal-cataract system receives Health Canada approval By Investing.com - Investing.com South Africa
Alcon to acquire LumiThera for dry AMD treatment device - MSN
Alcon to purchase LumiThera - Eyes On Eyecare
Alcon's Unity VCS Gets Health Canada Approval - Nasdaq
Alcon snaps up LumiThera for light-based AMD treatment - Optics.org
Alcon Gets Health Canada Approval on Unity Vitreoretinal Cataract System - MarketScreener
Alcon’s vitreoretinal-cataract system receives Health Canada approval - Investing.com
Alcon : Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - MarketScreener
Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval - Nasdaq
La dernière technologie chirurgicale révolutionnaire d’Alcon, Unity VCS, reçoit l’approbation de Santé Canada - New Castle News
Alcon Eyes Vitreoretinal Surgery Market Expansion in LumiThera Deal - MarketScreener
Alcon to acquire LumiThera and its dry AMD light therapy device - Investing.com Australia
Alcon Inc (ALC) Announces Approval of Clareon PanOptix Pro Intraocular Lens - MSN
Alcon's Bold Bet on Light Therapy: A New Dawn for Dry AMD and Retinal Dominance - AInvest
Alcon To Acquire LumiThera - citybiz
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times
2.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):